Previous close | 11.50 |
Open | 11.13 |
Bid | 11.19 x N/A |
Ask | 11.64 x N/A |
Day's range | 11.13 - 11.19 |
52-week range | 5.36 - 15.60 |
Volume | |
Avg. volume | 1,185 |
Market cap | 2.399B |
Beta (5Y monthly) | 0.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.10 |
Earnings date | 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.75 |
Jefferies has downgraded Hims & Hers Health (HIMS) to Hold from Buy, lowering its price target to $15. The analysts behind the call say expectations have now caught up to reality, limiting potential upside for the company’s numbers. Julie Hyman and Josh Lipton break down the details, questioning whether there are other categories where Hims & Hers would benefit from virtual subscribing, beyond hair loss and erectile dysfunction. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy.
SAN FRANCISCO, April 15, 2024--Hims & Hers Health, Inc. ("Hims & Hers," NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2024 financial results after the market closes on Monday, May 6, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.
SAN FRANCISCO, April 04, 2024--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Christopher Payne to the company’s Board of Directors.